News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Collegium Pharmaceutical, Inc. Receives FDA Fast Track Designation for Tamper Resistant, Chronic Pain Product, COL-172


6/10/2010 9:32:56 AM

CUMBERLAND, R.I.--(BUSINESS WIRE)--Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of COL-172 for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time. COL-172, a tamper resistant, extended release oral opioid formulation, is the Company’s second product candidate incorporating its proprietary DETERx™ technology for which it has filed an IND application. The Company’s lead product candidate, COL-003, is currently in late stage clinical development and has also been granted Fast Track Designation by the FDA.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES